Drug Profile
TBI 304
Alternative Names: HRC-304; TBI 304H; TBI-304Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Hemosol BioPharma
- Developer Therapure Innovations
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action CD163 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced anaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Chemotherapy-induced-anaemia in USA (Parenteral)
- 10 Sep 2020 Phase-I development is ongoing for Chemotherapy-induced-anaemia in USA (Parenteral) (Therapure Biopharma pipeline, September 2020)
- 28 May 2018 No recent reports of development identified for phase-I development in Chemotherapy-induced-anaemia in USA (Parenteral)